Hemo Organic Limited will seek shareholder approval to raise funds in one or more tranches through the issue of equity shares and/or convertible securities, including convertible warrants, via methods such as preferential allotment, private placement, or public issue, according to a regulatory filing with the BSE Limited on September 19, 2026. The company’s trading window will be closed from the end of business hours on September 19, 2026, until 48 hours after the conclusion of the board meeting scheduled for September 23, 2026.